GENELUX Corp

GENELUX Corp (GNLX) priced its initial public offering on Jan 26, 2023 at $6.00 per share, within its $6.00–$7.00 range, raising $15M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $141.9M. Benchmark was lead-left underwriter, joined by Brookline and Arcadia. Cooley advised the company and Nelson Mullins advised the underwriters.

Genelux Corp is a clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies for aggressive, hard-to-treat solid tumors. Its lead candidate, Olvi-Vec, a modified vaccinia virus, met its Phase 2 endpoint in platinum-resistant or refractory ovarian cancer.

Status

IPO

Ticker

GNLX

Exchange

Nasdaq Capital Market

Priced

Jan 26, 2023

IPO price

$6.00

Price range

$6.00–$7.00

Raised

$15M

Market cap at IPO price

$141.9M

First filed

Jun 24, 2022

Underwriters

Benchmark, Brookline and Arcadia

Company counsel

Cooley

Underwriters' counsel

Nelson Mullins

Sector

Biotech & pharma

Country / state

CA

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.